公开(公告)号：US11906519B2

公开(公告)日：2024-02-20

申请号：US16321745

申请日：2017-07-27

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Chengcheng Zhang ,  Zhiqiang An ,  Ningyan Zhang ,  Mi Deng ,  Jaehyup Kim ,  Xun Gui

IPC: G01N33/574 ,  G01N15/14 ,  G01N21/64 ,  G01N33/50 ,  G01N33/49 ,  G01N15/00 ,  G01N15/10

CPC classification number: G01N33/57426 ,  G01N15/14 ,  G01N21/6428 ,  G01N21/6456 ,  G01N33/4915 ,  G01N33/5023 ,  G01N33/57492 ,  G01N2015/0065 ,  G01N2015/1006 ,  G01N2021/6439

Abstract: Provided herein are methods and compositions for the identification of modulators of ApoE-induced LILRB activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor of ApoE-induced LILRB activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of ApoE-induced LILRB activation to a subject.

公开(公告)号：US11498963B2

公开(公告)日：2022-11-15

申请号：US16678049

申请日：2019-11-08

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Chengcheng Zhang ,  Mi Deng ,  Wei Xiong ,  Zhiqiang An ,  Ningyan Zhang ,  Xun Gui ,  Junke Zheng

IPC: A61K39/00 ,  C07K16/28 ,  G01N33/574 ,  C12N15/113 ,  A61P35/02 ,  A61K39/395 ,  A61K45/06 ,  C07K16/30

Abstract: The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.

公开(公告)号：US12202895B2

公开(公告)日：2025-01-21

申请号：US17275838

申请日：2019-09-12

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  IMMUNE-ONC THERAPEUTICS, INC.

Inventor： Zhiqiang An ,  Chengcheng Zhang ,  Ningyan Zhang ,  Xun Gui ,  Mi Deng ,  Tao Huang ,  Qiang Liu ,  X. Charlene Liao

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61K47/68 ,  A61K47/69 ,  A61K51/10 ,  A61P35/02 ,  G01N33/574

Abstract: The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.

公开(公告)号：US11377491B2

公开(公告)日：2022-07-05

申请号：US16475223

申请日：2018-01-02

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： X. Charlene Liao ,  Qiang Liu ,  Zhiqiang An ,  Ningyan Zhang ,  Xun Gui ,  Chengcheng Zhang ,  Mi Deng ,  Jingjing Xie

IPC: C07K16/28 ,  C12N5/12 ,  C12N15/85

Abstract: The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.